Mavenir in Collaboration with Intel Delivers Optimised Performance and Power Efficiency for 4G and 5G Open vRAN Solution
24.2.2024 14:37:00 EET | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces availability of its cutting-edge Open vRAN solution powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost – delivering a cloud-native, high-performance and energy-efficient solution for latency-sensitive and compute-intensive mobile network applications. The move to Intel’s recent processors for vRAN marks the latest solution optimisation for Mavenir, which has driven Open RAN momentum through three generations of Intel Xeon Scalable processors.
Mavenir's Open vRAN solution, powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost, offers an exceptional suite of performance, functionality, and integrated artificial intelligence (AI) and machine learning (ML) application for the next generation 4G and 5G networks. Mavenir has built a close and long-standing technology collaboration with Intel, and the adoption of Intel’s processors enables the development of more efficient and cost-effective RANs. These optimisations are being achieved through the availability of more processing power with higher capacity, resulting in reduction of number of cores or servers needed per cell site.
Mavenir's Open vRAN solution comprises the virtualised distributed Unit (vDU) and the centralised unit (vCU), supporting all mobile network generations (2G, 4G, 5G) and providing a complete baseband unit (BBU) functionality. The solution is cloud-native and easily deployable on Intel architecture-based private, hybrid, or public clouds. The Mavenir vDU incorporates Intel’s FlexRAN reference software, which utilises modular, virtualised control functions across well-defined interfaces that allow flexible and programmable control of the layer 1 wireless infrastructure.
The fully integrated vRAN acceleration feature of 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost eliminates the need for an external acceleration card and delivers up to 2x capacity increase with an additional 20% power savings1 versus the previous generation processor for applications like massive MIMO (mMIMO). This fully integrated solution allows Mobile Network Operators (MNOs) to deploy cloud-native, energy-efficient and AI-driven RAN solutions at a significantly lower cost.
Mavenir's pioneering Open vRAN solution has driven significant industry progress for Open RAN technology, and made Open RAN a mainstream consideration for all operators expanding their 4G and 5G networks, whether building new networks from scratch or upgrading existing ones. The combination sets the stage for more significant advances in next-generation O-RANs including dramatic energy savings, RAN slice assurance, AI/ML-powered SLAs, expanded RAN capacity, and optimised functionality splits.
BG Kumar, President, Access Networks, Platforms and Digital Enablement for Mavenir commented: “Mavenir values our ongoing collaboration with Intel, which is leading the industry in driving forward high-performance and sustainable Open vRAN solutions for 4G and 5G networks. Mavenir’s integrated solution powered by 4th Gen Intel Xeon Scalable processors with Intel vRAN Boost optimises the Open vRAN solution offerings even further– giving CSPs worldwide the ability to deploy cloud-native, energy-efficient, and cost-effective AI/ML powered RAN infrastructure built on world-class technology.”
Cristina Rodriguez, Vice President and General Manager, Wireless Access Networking Division at Intel said: “Operators’ journey to design and deploy new networks drives a key set of technology needs and challenges to be addressed. Mavenir’s solution leverages the best features of Intel’s 4th Gen Intel Xeon platform to provide operators a flexible solution with advanced functionalities to meet the diverse needs of both greenfield and brownfield operators.”
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realise the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
Meet Mavenir at Mobile World Congress 2024 (Barcelona, Feb 26 – 29 2024)
To explore our latest innovations, MWC show announcements and learn more about how Mavenir is delivering the Future of Networks – Today, visit our team in Hall 2 (Stand 2H60).
____________________________
1 For workloads and configurations visit www.Intel.com/PerformanceIndex. Results may vary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223458554/en/
Contact information
Mavenir PR Contact:
Emmanuela Spiteri
PR@mavenir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom